中新网广州12月21日电 (记者 蔡敏婕)带状疱疹并非老年人"专属疾病"，免疫功能受损的中青年群体同 样面临较高发病风险。 由广东省预防医学会主办的"2025年广东省疾病防控能力提升学习班"20日在广州举行，强调需重点关注 免疫缺陷人群与慢性基础病患者的疫苗接种工作，通过医防融合提升疾病防控水平。 广东省人民医院风湿免疫科主任医师李玲指出，带状疱疹的高危人群主要分为两类，一类是本身免疫监 视功能降低的患者，涵盖风湿免疫科疾病、血液肿瘤、实体瘤等人群；另一类是因治疗需要使用糖皮质 激素、免疫抑制剂、生物制剂等药物的群体，这类药物会进一步削弱人体免疫功能，提升感染风险。 "以往大家普遍认为带状疱疹是老年病，现在发现只要免疫功能受损，18岁以上的中青年群体也可能患 病。"李玲解释，带状疱疹由水痘-带状疱疹病毒再激活引发，小时候得过水痘的人，病毒会潜伏在体内 神经节中，当免疫功能下降时，病毒就可能被激活，从而引发带状疱疹。 疫苗接种是预防带状疱疹最有效的手段。不过李玲特别提醒，免疫缺陷人群在疫苗选择上有特殊要求， 风湿免疫科临床不推荐使用减毒活疫苗，建议优先选择灭活疫苗或重组疫苗，这类疫苗安全性更高，不 易诱发疾病复 ...

Core Viewpoint - The biopharmaceutical industry in China is rapidly developing, with significant growth expected in market size from 257.65 billion yuan in 2018 to 454.17 billion yuan in 2024, and projected to reach 460 billion yuan by 2025 [1][6][4]. Group 1: Definition and Classification - Biopharmaceuticals are products used for prevention, treatment, and diagnosis, developed using principles from microbiology, biology, medicine, biochemistry, and biotechnology [2][4]. - The biopharmaceutical industry can be categorized into biopharmaceuticals, chemical drugs, and modern traditional Chinese medicine, with biopharmaceuticals further divided into blood products, recombinant proteins, vaccines, monoclonal antibodies, and cell therapy products [2]. Group 2: Current Development Status - The development of the biopharmaceutical industry is closely linked to innovations in biotechnology, with significant advancements since the 20th century [4][6]. - China's biopharmaceutical market is still in its early stages but is experiencing strong growth, with biopharmaceuticals becoming a crucial part of the pharmaceutical sector [6][4]. Group 3: Industry Chain - The upstream of the biopharmaceutical industry consists of raw materials, pharmaceutical equipment, and biotechnology, with raw materials primarily sourced from natural biological materials [8]. - The midstream involves the research and production of biopharmaceutical products, while the downstream focuses on sales channels to medical institutions, diagnostic agencies, research units, and consumers [8]. Group 4: Development Environment and Policies - Recent policies have supported and regulated the development of the biopharmaceutical industry, focusing on improving new drug pricing mechanisms, drug price governance, centralized procurement, and medical service standardization [10][12]. Group 5: Competitive Landscape - The biopharmaceutical industry is a strategic emerging industry in China, with notable companies including WuXi AppTec, HengRui Medicine, and BeiGene, among others [13][15]. - Various segments within the biopharmaceutical industry have seen the emergence of leading companies, such as vaccine producers and diagnostic reagent manufacturers [15][20]. Group 6: Development Trends - There is a strong emphasis on developing new vaccines and improving traditional vaccines to meet global health challenges [25]. - The industrialization of antibody drugs and protein drugs is advancing, with significant roles in treating various diseases [26][27]. - Research and product development in diagnostic and detection technologies for major diseases are increasingly utilizing nanomaterials for enhanced sensitivity and specificity [28].